Tracleer (bosentan) / J&J, Roche 
Welcome,         Profile    Billing    Logout  
 135 Diseases   28 Trials   28 Trials   1184 News 


12345678910111213»
  • ||||||||||  Tracleer (bosentan) / J&J, Roche, Bridion (sugammadex) / Merck (MSD)
    Considerations in the Management of a Down Syndrome Patient With Severe Pulmonary Hypertension Presenting With an Acute Abdomen (126A) -  Jun 25, 2024 - Abstract #ASA2024ASA_3042;    
    Her medications include sildenafil, bosentan, treprostinil, levothyroxine, and ranitidine...You give two mg of Midazolam, 50 mg of Ketamine, 50 mcg of Fentanyl, 50 mg of Rocuronium, and start Propofol infusion at 200 mcg/kg/min...Why?-What would you do for pain control?-What would be your post-op disposition for this patient?Intraoperative continued: You decide to perform awake extubation, so you discontinue Propofol infusion and give Sugammadex for reversal...ABG shows pH 7.35, PaCO2 40, PaO2 85, BE -3, and lactate 2. You extubate the patient and transfer to CICU in stable condition.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche, Bridion (sugammadex) / Merck (MSD)
    Considerations in the Management of a Down Syndrome Patient With Severe Pulmonary Hypertension Presenting With an Acute Abdomen (126A) -  Jun 25, 2024 - Abstract #ASA2024ASA_128;    
    Her medications include sildenafil, bosentan, treprostinil, levothyroxine, and ranitidine...You give two mg of Midazolam, 50 mg of Ketamine, 50 mcg of Fentanyl, 50 mg of Rocuronium, and start Propofol infusion at 200 mcg/kg/min...Why?-What would you do for pain control?-What would be your post-op disposition for this patient?Intraoperative continued: You decide to perform awake extubation, so you discontinue Propofol infusion and give Sugammadex for reversal...ABG shows pH 7.35, PaCO2 40, PaO2 85, BE -3, and lactate 2. You extubate the patient and transfer to CICU in stable condition.
  • ||||||||||  Tryvio (aprocitentan) / J&J
    Journal:  Aprocitentan (Tryvio) for hypertension. (Pubmed Central) -  Jun 21, 2024   
    You extubate the patient and transfer to CICU in stable condition. No abstract available
  • ||||||||||  Retrospective data, Review, Journal:  Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta-analysis. (Pubmed Central) -  May 24, 2024   
    Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual-drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    Pulmonary Hypertension in a Cystic Fibrosis Child Following COVID 19: Case Report (Exhibit Hall, Salon 9) -  May 20, 2024 - Abstract #FOCIS2024FOCIS_448;    
    Pulmonary arterial hypertension should be suspected in a CF patient presenting after COVID 19 with worsened respiratory status, unexplained desaturation, night sleep disturbances. The prevention of COVID 19 in CF cohort should be prioritized.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    Generation and utilisation of an advanced iPSC-derived hepatocyte model for cholestasis modelling (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1939;    
    DIC was induced with bosentan, a BSEP inhibitor, or by feeding excess chenodeoxycholic acid for 6 days... Our new iHEP model provides a more physiologically relevant platform for human cholestasis modelling, offering insights into disease mechanisms and facilitating screening of compounds that cause DIC.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    ANTI-CD19 CAR T CELL THERAPY FOR REFRACTORY CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2571;    
    Rapid improvement of pulmonary hypertension allowed bosentan discontinuation at wk 4...Learning points for clinical practice: Anti-CD19 CAR-T cell therapy is effective in adolescent with severe SLE. The long-term remission is to be established.
  • ||||||||||  Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
    A PAH Drug Ranking Strategy for Individualized Combination Therapy Via Pulmonary Endoarterial Biopsy (San Diego Convention Center, Room 25A-C (Upper Level)) -  Mar 17, 2024 - Abstract #ATS2024ATS_8762;    
    This study demonstrates the utility of combining an endoarterial biopsy technique with genetic expression studies to generate a ranking system that can be used to select a potentially more effective drug or drug combination regimen for an individual patient at a certain a stage of PAH disease. Human studies will be necessary to demonstrate the utility of this approach.
  • ||||||||||  hydrocortisone / Generic mfg.
    Effect of Hydrocortisone (HC) on Cardiac Mass in Preterm Intubated Infants < 30 weeks Gestational Age (Convention Center Exhibit Hall) -  Mar 16, 2024 - Abstract #PAS2024PAS_4336;    
    Spearman Background: Dexamethasone use in preterm infants has been associated with adverse effects including hypertension, and an increase in the left ventricular mass index (LVMI), a surrogate for left ventricular hypertrophy...None of the infants in the HC group were receiving sildenafil or bosentan at 36 weeks
  • ||||||||||  Tracleer (bosentan) / J&J, Roche, Rituxan (rituximab) / Roche
    Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus () -  Feb 25, 2024 - Abstract #LUPUS2024LUPUS_282;    
    She was started on sildenafil and bosentan for PAH...Anti-CD19 CAR-T cell therapy was considered and performed after lymphodepletion with CYC (1500mg/m2) and fludarabine (90mg/m2)...Conclusions In this SLE patient with severe refractory disease, B-cell depletion and drug-free remission were rapidly achieved after anti-CD19 CAR-T cells infusion. Long-term efficacy assessment is needed.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Tracleer (bosentan) / J&J, Roche
    THE PATTERN OF MEDICATION USE SIGNIFICANTLY CHANGED OVER 36 MONTHS OBSERVATION PERIOD (Poster Area) -  Feb 13, 2024 - Abstract #SSWC2024SSWC_360;    
    This is more frequent than typical adult SSc practice but coincides with jSSc SHARE treatment recommendations(#1). After 36 months observation over 90% of patients received a DMARD therapy.
  • ||||||||||  Opsumit (macitentan) / Nippon Shinyaku, J&J
    EFFICACY AND SAFETY OF MACITENTAN IN REFRACTORY DIGITAL ULCERS (Poster Area) -  Feb 13, 2024 - Abstract #SSWC2024SSWC_332;    
    Most patients (90.9%) had received previously treatment with Bosentan, and the reason for withdrawal was inefficacy in 4 cases (40%) and adverse effects (liver toxicity) in 6 (60%). Our data show that Macitentan is an effective agent for ischemic digital refractory ulcers in patients suffering from SARDs with a favorable safety profile in clinical practice.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    BOSENTAN ACCELERATES DELAYED WOUND HEALING IN EPITHELIAL CELL-SPECIFIC FLI1 KNOCKOUT MICE BY RESTORING IMPAIRED REEPITHELIALIZATION (Poster Area) -  Feb 13, 2024 - Abstract #SSWC2024SSWC_58;    
    These results indicate that wound healing is delayed in Fli1 KcKO mice due to dysregulated reepithelialization and ECM remodeling, and that bosentan-dependent acceleration of Fli1-deficient keratinocyte migration contributes to the restoration of delayed wound healing in Fli1 KcKO mice. In human SSc, bosentan may act on keratinocytes and accelerate the healing of microtrauma, contributing to preventing the development of new digital ulcers.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    Retrospective data, Review, Journal:  Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis. (Pubmed Central) -  Feb 8, 2024   
    In human SSc, bosentan may act on keratinocytes and accelerate the healing of microtrauma, contributing to preventing the development of new digital ulcers. Bosentan is effective in the treatment of persistent pulmonary hypertension of the newborn but adverse reactions such as abnormal liver function should be observed when using it.
  • ||||||||||  Ventavis (iloprost) / Bayer, J&J, University of Copenhagen, Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
    P4 data, Journal, Real-world evidence, Real-world:  Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data. (Pubmed Central) -  Jan 9, 2024   
    According to the results of the study, bosentan had the highest risk of liver injury and the combination regimens bosentan?+?sildenafil, bosentan?+?epoprostenol, and bosentan?+?iloprost had a stronger risk of liver injury. From the early stages of treatment, we need to regularly monitor the liver function of patients, especially for females and the elderly, and discontinue the suspected drug as soon as the liver injury occurs.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    Journal:  Bosentan does not affect renal resistive index in scleroderma/systemic sclerosis patients. (Pubmed Central) -  Dec 25, 2023   
    From the early stages of treatment, we need to regularly monitor the liver function of patients, especially for females and the elderly, and discontinue the suspected drug as soon as the liver injury occurs. In conclusion, in patients with SSc complicated by digital ulcers and normal to mildly diminished kidney function, bosentan had no effect on intrarenal hemodynamics, but reduced blood pressure levels and kidney function.
  • ||||||||||  Tracleer (bosentan) / J&J, Roche
    Review, Journal:  The Pathogenesis of Systemic Sclerosis: The Origin of Fibrosis and Interlink with Vasculopathy and Autoimmunity. (Pubmed Central) -  Sep 28, 2023   
    Although vasculopathy is an important initial step of the pathogenesis for SSc, it is still unclear how vasculopathy is related to inflammation and fibrosis. In this review, we focused on the clinical evidence for vasculopathy, the major cellular players for the pathogenesis, including pericytes, adipocytes, endothelial cells (ECs), and myofibroblasts, and their signaling pathway to elucidate the relationship among vasculopathy, inflammation, and fibrosis in SSc.
  • ||||||||||  Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3585;    
    This is the first meta-analysis on CTD-PAH that reported the pooled analysis of change in functional class, hemodynamic measurements (RAP, PVR, CI), and NT-proBNP, some of which have important prognostic value for PAH. Improvement in exercise capacity and reduction in risk of CW in CTD-PAH patients were less pronounced compared to idiopathic PAH (IPAH).